Northwestern Mutual Investment Management Company LLC Takes $359,000 Position in Glaukos Corporation (GKOS)

Northwestern Mutual Investment Management Company LLC bought a new stake in Glaukos Corporation (NYSE:GKOS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 14,623 shares of the medical instruments supplier’s stock, valued at approximately $359,000.

Other hedge funds also recently made changes to their positions in the company. American International Group Inc. boosted its stake in shares of Glaukos Corporation by 7.1% in the first quarter. American International Group Inc. now owns 10,293 shares of the medical instruments supplier’s stock valued at $528,000 after buying an additional 681 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock valued at $953,000 after buying an additional 1,506 shares in the last quarter. Great West Life Assurance Co. Can purchased a new stake in shares of Glaukos Corporation in the first quarter valued at approximately $102,000. BNP Paribas Arbitrage SA boosted its stake in shares of Glaukos Corporation by 740.6% in the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 3,118 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Glaukos Corporation by 77.6% in the second quarter. Legal & General Group Plc now owns 7,240 shares of the medical instruments supplier’s stock valued at $299,000 after buying an additional 3,164 shares in the last quarter.

Shares of Glaukos Corporation (NYSE:GKOS) opened at 31.40 on Friday. The stock’s market capitalization is $1.08 billion. The firm’s 50-day moving average price is $37.87 and its 200-day moving average price is $41.45. Glaukos Corporation has a 52-week low of $28.72 and a 52-week high of $52.49.

In other Glaukos Corporation news, Director Orbimed Advisors Llc sold 325,000 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $37.93, for a total transaction of $12,327,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total value of $3,051,871.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 980,200 shares of company stock valued at $37,900,263. 16.40% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Northwestern Mutual Investment Management Company LLC Takes $359,000 Position in Glaukos Corporation (GKOS)” was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://transcriptdaily.com/2017/09/17/northwestern-mutual-investment-management-company-llc-takes-359000-position-in-glaukos-corporation-gkos.html.

A number of analysts recently weighed in on the company. BidaskClub upgraded Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald restated a “buy” rating and issued a $60.00 price target (up from $54.00) on shares of Glaukos Corporation in a research note on Thursday. Zacks Investment Research downgraded Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Roth Capital decreased their price target on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $56.00 price target on shares of Glaukos Corporation in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $49.86.

Glaukos Corporation Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply